Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Details

Serval ID
serval:BIB_7085992140C0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Journal
Current urology reports
Author(s)
Pozzessere C., Bassanelli M., Ceribelli A., Rasul S., Li S., Prior J.O., Cicone F.
ISSN
1534-6285 (Electronic)
ISSN-L
1527-2737
Publication state
Published
Issued date
11/10/2019
Peer-reviewed
Oui
Volume
20
Number
11
Pages
68
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
To critically review the potential clinical applications of prostate-specific membrane antigen (PSMA) radioactive ligands in renal cell carcinoma (RCC).
Radioactive probes targeting PSMA hold promise in several malignancies in addition to prostate cancer, owing to the expression of PSMA by tumor neovasculature. The majority of clear cell RCCs (ccRCC), the most malignant RCC subtype, express PSMA on tumor-associated neovasculature. The endothelium of less aggressive RCC subtypes is PSMA positive in a lower, but still significant percentage of cases. PSMA might therefore represent an interesting theragnostic target in RCC. The preliminary data available suggest a potential role for PSMA-targeting radiopharmaceuticals in complementing conventional imaging for staging ccRCC patients at risk of nodal involvement and oligometastatic disease. Additional applications of PSMA imaging may be the selection and the response assessment of patients receiving anti-angiogenic treatments. The effectiveness of PSMA-targeting radionuclide therapy should also be investigated.
Keywords
Antigens, Surface/metabolism, Antineoplastic Agents/therapeutic use, Carcinoma, Renal Cell/diagnostic imaging, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/metabolism, Glutamate Carboxypeptidase II/metabolism, Humans, Kidney Neoplasms/diagnostic imaging, Kidney Neoplasms/drug therapy, Kidney Neoplasms/metabolism, Neoplasm Staging, Positron Emission Tomography Computed Tomography/methods, Radiopharmaceuticals, Treatment Outcome, Diagnostic imaging, Neoangiogenesis, Positron-emission tomography, Prostate-specific membrane antigen, Renal cell carcinoma, Response assessment
Pubmed
Web of science
Create date
13/10/2019 18:32
Last modification date
24/01/2020 6:26
Usage data